Abbisko Therapeutics and X4 Pharmaceuticals Announce Positive Phase III Results for Mavorixafor in WHIM Syndrome
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) and its US partner X4 Pharmaceuticals Inc....
Rare / orphan disease drugs
CStone Pharmaceuticals’ Partner Servier Secures EU Approvals for IDH1 Inhibitor Tibsovo
CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has announced receiving two new indication approvals for...
US FDA Nears Regulatory Decision on Junshi Biosciences’ PD-1 Inhibitor Tuoyi
China-based Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is approaching a significant regulatory milestone...
Suzhou GenAssist’s GEN6050 Receives US FDA Pre-IND Acceptance for Duchenne Muscular Dystrophy Treatment
China-based Suzhou GenAssist Therapeutic Co., Ltd has announced that the US Food and Drug Administration...
Reistone Biopharma’s Edralbrutinib Earns Orphan Drug Designation for NMOSD from US FDA
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Medicine with an investment of USD...
Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy
Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of...
Roche’s Q1 2023 Report: 3% Dip in Revenues with Strong Growth in Pharmaceuticals
Roche (SWX: ROG), the Swiss pharmaceutical and diagnostics giant, reported a 3% year-on-year (YOY) decrease...
Junshi Biosciences Submits Market Filings for PCSK9 mAb Ongericimab to NMPA
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced the submission of two market filings...
Belief BioMed Completes Patient Dosing in Phase III Hemophilia B Gene Therapy Trial
Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced the completion of patient dosing...
ChengDu ShengNuo Biotech Secures NMPA Approval for Generic Firazyr Equivalent
ChengDu ShengNuo Biotech Co., Ltd (SHA: 688117), a China-based polypeptide specialist, has announced that it...
PharmaEssentia Corporation Completes Secondary Offering of GDR Shares on Luxembourg Exchange
Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of...
Convalife Pharmaceuticals’ Mefuparib Earns Orphan Drug Designation for Cholangiocarcinoma
Shanghai-based Convalife Pharmaceuticals has announced that it has received orphan drug designation (ODD) status from...
Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE
The Center for Drug Evaluation (CDE) website has indicated that Huahui Health’s HH-003, Boehringer Ingelheim’s...
Bristol-Myers Squibb Launches Zeposia in China for Multiple Sclerosis Treatment
Global pharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced the market launch in China...
Vcanbio Receives CDE Approval for VUM02 Clinical Trial in Idiopathic Pulmonary Fibrosis
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...
Abbisko Therapeutics Secures Orphan Drug Designation for FGFR4 Inhibitor ABSK012
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received orphan...
Fosun Pharmaceutical Gets NMPA Approval for FCN-159 Phase II Study in LCH
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...
Transcenta’s Osemitamab Receives FDA Orphan Drug Designation for Pancreatic Cancer
China-based biotechnology company Transcenta Holdings Ltd (HKG: 6628) has announced that its drug TST001 (osemitamab),...
Hengrui Pharmaceuticals’ HRS-5965 Receives NMPA Approval for Clinical Study in Hemolytic Anemia
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval...
Fosun Pharma’s Generic Remodulin Gains NMPA Approval for Pulmonary Arterial Hypertension
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its generic...